An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable

Detalhes bibliográficos
Autor(a) principal: Oliveira-Neto,Manoel Paes de
Data de Publicação: 2006
Outros Autores: Mattos,Marise da Silva
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Sociedade Brasileira de Medicina Tropical
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822006000400001
Resumo: Despite more than half a century of use in leishmaniasis, antimony therapy still presents serious problems concerning dosage and toxicity. Low and high doses have been shown to be equally effective. In this paper, the feasibility of injecting one ampoule of meglumine antimoniate intramuscularly every other day until clinical cure is demonstrated, while studying a series of 40 cutaneous leishmaniasis cases. Total dose used varied from 1,822.5 to 12,150mg of pentavalent antimony and total time of treatment varied from 3 to 10 weeks, with 86% efficacy. Thirty-six out of the 40 patients are still on follow-up with a mean time of 10.7 ± 7 months and a median of 9 months. No relapse or mucosal lesions have been noted so far. The schedule showed good tolerance and easy application and its efficacy was comparable to the officially recommended WHO schedule. Therefore, such a schedule represents a valuable alternative for the cases with high toxicicity to antimony or daily injections are an obstacle to the treatment.
id SBMT-1_8b3b447843e587a22571e1aa482df406
oai_identifier_str oai:scielo:S0037-86822006000400001
network_acronym_str SBMT-1
network_name_str Revista da Sociedade Brasileira de Medicina Tropical
repository_id_str
spelling An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirableCutaneous leishmaniasisPentavalent antimonyLow doseSystemic therapyDespite more than half a century of use in leishmaniasis, antimony therapy still presents serious problems concerning dosage and toxicity. Low and high doses have been shown to be equally effective. In this paper, the feasibility of injecting one ampoule of meglumine antimoniate intramuscularly every other day until clinical cure is demonstrated, while studying a series of 40 cutaneous leishmaniasis cases. Total dose used varied from 1,822.5 to 12,150mg of pentavalent antimony and total time of treatment varied from 3 to 10 weeks, with 86% efficacy. Thirty-six out of the 40 patients are still on follow-up with a mean time of 10.7 ± 7 months and a median of 9 months. No relapse or mucosal lesions have been noted so far. The schedule showed good tolerance and easy application and its efficacy was comparable to the officially recommended WHO schedule. Therefore, such a schedule represents a valuable alternative for the cases with high toxicicity to antimony or daily injections are an obstacle to the treatment.Sociedade Brasileira de Medicina Tropical - SBMT2006-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822006000400001Revista da Sociedade Brasileira de Medicina Tropical v.39 n.4 2006reponame:Revista da Sociedade Brasileira de Medicina Tropicalinstname:Sociedade Brasileira de Medicina Tropical (SBMT)instacron:SBMT10.1590/S0037-86822006000400001info:eu-repo/semantics/openAccessOliveira-Neto,Manoel Paes deMattos,Marise da Silvaeng2006-09-25T00:00:00Zoai:scielo:S0037-86822006000400001Revistahttps://www.sbmt.org.br/portal/revista/ONGhttps://old.scielo.br/oai/scielo-oai.php||dalmo@rsbmt.uftm.edu.br|| rsbmt@rsbmt.uftm.edu.br1678-98490037-8682opendoar:2006-09-25T00:00Revista da Sociedade Brasileira de Medicina Tropical - Sociedade Brasileira de Medicina Tropical (SBMT)false
dc.title.none.fl_str_mv An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
title An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
spellingShingle An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
Oliveira-Neto,Manoel Paes de
Cutaneous leishmaniasis
Pentavalent antimony
Low dose
Systemic therapy
title_short An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
title_full An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
title_fullStr An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
title_full_unstemmed An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
title_sort An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable
author Oliveira-Neto,Manoel Paes de
author_facet Oliveira-Neto,Manoel Paes de
Mattos,Marise da Silva
author_role author
author2 Mattos,Marise da Silva
author2_role author
dc.contributor.author.fl_str_mv Oliveira-Neto,Manoel Paes de
Mattos,Marise da Silva
dc.subject.por.fl_str_mv Cutaneous leishmaniasis
Pentavalent antimony
Low dose
Systemic therapy
topic Cutaneous leishmaniasis
Pentavalent antimony
Low dose
Systemic therapy
description Despite more than half a century of use in leishmaniasis, antimony therapy still presents serious problems concerning dosage and toxicity. Low and high doses have been shown to be equally effective. In this paper, the feasibility of injecting one ampoule of meglumine antimoniate intramuscularly every other day until clinical cure is demonstrated, while studying a series of 40 cutaneous leishmaniasis cases. Total dose used varied from 1,822.5 to 12,150mg of pentavalent antimony and total time of treatment varied from 3 to 10 weeks, with 86% efficacy. Thirty-six out of the 40 patients are still on follow-up with a mean time of 10.7 ± 7 months and a median of 9 months. No relapse or mucosal lesions have been noted so far. The schedule showed good tolerance and easy application and its efficacy was comparable to the officially recommended WHO schedule. Therefore, such a schedule represents a valuable alternative for the cases with high toxicicity to antimony or daily injections are an obstacle to the treatment.
publishDate 2006
dc.date.none.fl_str_mv 2006-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822006000400001
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822006000400001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0037-86822006000400001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical - SBMT
publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical - SBMT
dc.source.none.fl_str_mv Revista da Sociedade Brasileira de Medicina Tropical v.39 n.4 2006
reponame:Revista da Sociedade Brasileira de Medicina Tropical
instname:Sociedade Brasileira de Medicina Tropical (SBMT)
instacron:SBMT
instname_str Sociedade Brasileira de Medicina Tropical (SBMT)
instacron_str SBMT
institution SBMT
reponame_str Revista da Sociedade Brasileira de Medicina Tropical
collection Revista da Sociedade Brasileira de Medicina Tropical
repository.name.fl_str_mv Revista da Sociedade Brasileira de Medicina Tropical - Sociedade Brasileira de Medicina Tropical (SBMT)
repository.mail.fl_str_mv ||dalmo@rsbmt.uftm.edu.br|| rsbmt@rsbmt.uftm.edu.br
_version_ 1752122153583509504